Background: High dose IL-2 (HD IL-2) can provide durable responses in patients with metastatic renal cell carcinoma (mRCC). PROCLAIM (www.proclaimregistry.com, NCT01415167) is an IL-2 registry with over 44 participating sites that captures real-world patient population survival and outcomes. Herein, we report on contemporary patient experience sequencing HD IL-2 with targeted therapy (TT) and immune checkpoint blockade (ICB) in mRCC. Methods: Patients were prospectively enrolled into the registry as of 2011 and must have received at least one dose of HD IL-2 for this analysis. Statistics and survival analysis were performed on datasets as of December 2, 2015. Results: The mOS for all mRCC patients (n=411) was not reached (NR), with a median follow-up of 21 months. The overall response rate (ORR) for the 382 patients with available data was 17.8%. The mOS for those who experienced complete response (CR, n=15), partial response (PR, n=53), or stable disease (SD, n=145) was not reached while in patients with progressive disease (PD, n=169), mOS was 17 months. Survival for patients treated with TT or ICB following HD IL-2 were further analyzed and described in Table 1. Treatments prior to HD IL-2 include chemotherapy (n=12), TT (n=74), immunotherapy (n=8), radiation (n=64), and surgery (n=389). Conclusions: This analysis of the national IL-2 registry reveals that HD IL-2 therapy followed by TT and/or ICB is potentially associated with survival benefit. HD IL-2 continues to be a valuable treatment option for eligible patients with mRCC. Clinical trial information: NCT01415167

TT may include inhibitors of VEGF, mTOR, or, EGFR pathways.